Woodline Partners LP Grows Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Woodline Partners LP raised its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 46.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 93,294 shares of the biotechnology company's stock after acquiring an additional 29,475 shares during the quarter. Woodline Partners LP owned approximately 0.08% of Viking Therapeutics worth $3,754,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Blue Trust Inc. boosted its position in Viking Therapeutics by 75.9% during the 4th quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 309 shares in the last quarter. YANKCOM Partnership bought a new stake in Viking Therapeutics during the 4th quarter valued at $33,000. FIL Ltd boosted its position in Viking Therapeutics by 116.8% during the 4th quarter. FIL Ltd now owns 1,203 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 648 shares in the last quarter. CIBC Private Wealth Group LLC boosted its position in shares of Viking Therapeutics by 170.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 1,351 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 851 shares in the last quarter. Finally, Kapitalo Investimentos Ltda acquired a new stake in shares of Viking Therapeutics in the 4th quarter worth $63,000. Institutional investors own 76.03% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Maxim Group lowered their price objective on Viking Therapeutics from $120.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Citigroup assumed coverage on Viking Therapeutics in a research report on Friday, February 7th. They issued a "neutral" rating and a $38.00 price objective for the company. Truist Financial reissued a "buy" rating and issued a $75.00 price objective (down previously from $95.00) on shares of Viking Therapeutics in a research report on Monday, April 28th. HC Wainwright reissued a "buy" rating and issued a $102.00 price objective on shares of Viking Therapeutics in a research report on Thursday, April 24th. Finally, Scotiabank assumed coverage on Viking Therapeutics in a research report on Thursday, February 13th. They issued a "sector outperform" rating and a $102.00 price objective for the company. One analyst has rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $87.15.

Insider Buying and Selling at Viking Therapeutics

In related news, Director Sarah Kathryn Rouan acquired 1,240 shares of Viking Therapeutics stock in a transaction on Monday, March 31st. The stock was acquired at an average price of $24.15 per share, for a total transaction of $29,946.00. Following the purchase, the director now owns 1,240 shares of the company's stock, valued at approximately $29,946. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 4.10% of the company's stock.

Viking Therapeutics Price Performance

VKTX traded down $0.93 on Friday, reaching $27.23. 985,859 shares of the stock were exchanged, compared to its average volume of 4,067,648. The company's 50-day moving average price is $25.78 and its 200 day moving average price is $34.10. Viking Therapeutics, Inc. has a fifty-two week low of $18.92 and a fifty-two week high of $81.73. The firm has a market capitalization of $3.06 billion, a PE ratio of -27.17 and a beta of 0.75.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.10). The business's quarterly revenue was up .0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.26) earnings per share. As a group, equities analysts forecast that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.